Respiratory syncytial virus (RSV) infection is associated with significant morbidity and mortality in patients with hematologic malignancy and in hematopoietic cell transplant (HCT) recipients \[[@CIT0001], [@CIT0002]\]. There are no approved treatments for RSV infection in HCT recipients, although several candidates are in development for treatment of RSV infections in various populations \[[@CIT0003]\], including HCT recipients \[[@CIT0007], [@CIT0008]\]. Historically, mortality rates in HCT recipients with lower respiratory tract infection (LRTI) due to RSV have been as high as 55% \[[@CIT0009]\]. However, more-recent studies of subjects with either upper respiratory tract infection (URTI) or LRTI have demonstrated substantially lower mortality rates (5%--10%), which may in part be due to improvements in transplantation practices, including the use of nonmyeloablative conditioning and changes in supportive care practices \[[@CIT0012], [@CIT0013]\]. Additional factors may reduce the reported mortality rates, such as the lack of clear delineation of disease site (upper versus lower respiratory tract) and the variation in LRTI definition. The strictest definition of LRTI requires detection of RSV in the lower respiratory tract \[[@CIT0009], [@CIT0010]\]; however, several studies use more-lenient definitions that rely on detection of RSV in the upper respiratory tract alone with LRTI symptoms and/or abnormal radiographic findings, without documentation of RSV in the lower respiratory tract \[[@CIT0011], [@CIT0012], [@CIT0014]\]. These variations in the LRTI definition can affect disease prevalence and outcome estimates, variables that influence clinical trial design. To assess this potential impact, we sought to evaluate RSV LRTI, defined by site of virologic detection, and its association with clinical manifestations and outcomes.

Despite heterogeneous definitions of RSV LRTI, mortality rates do appear to have declined over time and mortality as a clinical endpoint is thus not practical for use in clinical trials. Given the identification of several promising antivirals for the treatment of RSV disease, the need to define alternative surrogate endpoints that are clinically meaningful and reflect patient functionality becomes critical.

One such potential end point is the number of days an RSV-infected patient requires supplemental oxygen, a potential clinically meaningful endpoint that may correlate with acute lung injury. Supplemental oxygen use at diagnosis is associated with increased mortality in HCT recipients with RSV LRTI \[[@CIT0015]\]; however, supplemental oxygen use as an outcome has not been previously evaluated. The number of days during which supplemental oxygen was required was evaluated in a recent study of HCT recipients with parainfluenza virus LRTI \[[@CIT0016]\]: during the 28 days after infection diagnosis, subjects with virus detected in the lower respiratory tract (ie, those with proven or probable LRTI) had significantly more days during which supplemental oxygen was required than subjects with LRTI in whom virus was not detected in the lower respiratory tract (ie, those with possible LRTI) \[[@CIT0016]\]. Supplemental oxygen use has not been evaluated for other respiratory viruses, nor has this approach been assessed rigorously as a potential endpoint for clinical trials.

In the present study, we sought to define and compare outcomes, including mortality and days during which supplemental oxygen was required, in subjects with possible, probable, or proven RSV LRTI.

METHODS {#s5}
=======

Patients and Data Collection {#s6}
----------------------------

HCT recipients with virologically confirmed RSV infection between January 2003 and January 2015 were included in this study. Clinical data were collected from databases and supplemental review of the medical record. This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center. Subjects signed informed consent permitting the use of data for research. Subjects with incomplete data on supplemental oxygen use following the diagnosis of RSV infection were excluded.

At our institution, standard practice is to evaluate for lower respiratory tract disease in any HCT recipient with RSV detected in the upper respiratory tract. A patient was considered to have RSV URTI if they had an upper respiratory tract sample that tested positive for RSV and no RSV-positive LRTI specimen or radiographic abnormalities. A patient was considered to have RSV LRTI if they had an RSV-positive lower respiratory tract sample (ie, bronchoalveolar lavage \[BAL\], a lung biopsy specimen, or an autopsy specimen) with or without radiographic abnormalities (defined as proven or probable LRTI, respectively) or an RSV-positive upper respiratory tract sample with radiographic abnormalities (defined as possible LRTI). The day of RSV LRTI diagnosis was defined as the date when RSV was detected in the lower respiratory tract specimen (for cases of proven/probable LRTI) or the date the radiographic abnormality was detected (for cases of possible LRTI). Virologic confirmation was obtained by direct fluorescent antibody testing, shell vial centrifugation, or conventional viral culture of lower respiratory tract samples; after 2007, patients also had RSV detected by reverse transcription--polymerase chain reaction (PCR) analysis \[[@CIT0017]\].

Subjects were divided into 3 groups. Group 1 comprised patients with URTI at presentation without progression to LRTI; group 2 comprised patients with URTI at presentation with subsequent progression to proven, probable, or possible LRTI; and group 3 comprised patients with proven, probable, or possible LRTI at presentation.

Maximum supplemental oxygen use per 24-hour period was recorded for days 0 through 28 following initial RSV presentation, as well as for days 0 through 28 following LRTI diagnosis. Supplemental oxygen use was defined as the delivery of oxygen by any modality, including nasal cannula, mask, noninvasive positive pressure ventilation, or mechanical ventilation, and was recorded if sustained for \>4 hours. Supplemental oxygen administered in the context of medication administration and baseline supplemental oxygen use was not recorded. Supplemental oxygen was administered per standardized clinical nursing protocols at our center. A supplemental oxygen--free day was defined as any 24-hour period during which a subject received ≤2 L of supplemental oxygen per minute (sustained for a continuous 48-hour period) while the patient was alive. The impact of death on the number of supplemental oxygen--free days was evaluated using 2 definitions. For definition 1, the day of death and subsequent days up to 28 days following presentation were not considered supplemental oxygen-free days. For definition 2, if a subject died, none of the 28 days were considered supplemental oxygen--free days (ie, the number of supplemental oxygen--free days was 0).

Statistical Analysis {#s7}
--------------------

Patients were analyzed on the basis of their first episode of RSV following HCT; for those who presented with or progressed to LRTI, additional analyses were conducted beginning at the time of LRTI diagnosis. The probability of overall survival was estimated using the Kaplan-Meier method; the log-rank test was used to compare mortality curves between groups. Cox proportional hazard regression was used to evaluate unadjusted and adjusted hazard ratios (HRs) for the time to first use of supplemental oxygen and the time to mechanical ventilation. Covariates evaluated as candidate risk factors for inclusion in multivariable models are listed in [Table 1](#T1){ref-type="table"} and were selected a priori. Variables with a *P* value of ≤ 0.2 in univariable analysis were candidates for multivariable models and were retained in the models if they remained significant themselves or modified the effect of another factor (confounder). The median numbers of supplemental oxygen--free days while alive were compared among groups and within groups, divided into those with possible LRTI versus those proven/probable LRTI, by the Wilcoxon rank sum test. Two-sided *P* values of \<.05 were considered to be statistically significant. Sample size estimates were calculated using a 2-sided Pearson χ^2^ test, for mortality by day 28, and 2-sided *t* tests, for the number of supplemental oxygen--free days by day 28, with an α of 0.05 and 80% power. All statistical analyses were performed using SAS 9.4 for Windows (SAS Institute, Cary, NC).

###### 

Characteristics of Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection, by Group

  Variables                                                                      Whole Cohort (n = 230)   Group 1 (n = 143)   Group 2 (n = 54)    Group 3 (n = 33)
  ------------------------------------------------------------------------------ ------------------------ ------------------- ------------------- -------------------
  Recipient age at transplantation, y                                                                                                             
  Median (IQR)                                                                   50.0 (28.8--59.5)        48.5 (23.7--58.3)   51.2 (31.7--61.1)   51.8 (38.0--61.2)
   \<21                                                                          46 (20)                  31 (22)             11 (20)             4 (12)
   21--60                                                                        128 (56)                 82 (57)             27 (50)             19 (58)
   \>60                                                                          56 (24)                  30 (21)             16 (30)             10 (30)
  Year of transplantation                                                                                                                         
  2003--2010                                                                     135 (59)                 78 (55)             38 (70)             19 (58)
  2011--2015                                                                     85 (37)                  58 (41)             15 (28)             12 (36)
  2000--2002                                                                     10 (4)                   7 (5)               1 (2)               2 (6)
  Recipient sex                                                                                                                                   
  Male                                                                           136 (59)                 86 (60)             28 (52)             22 (67)
  Female                                                                         94 (41)                  57 (40)             26 (48)             11 (33)
  Race                                                                                                                                            
  White                                                                          151 (66)                 90 (63)             37 (69)             24 (73)
  Other than white                                                               68 (30)                  46 (32)             13 (24)             9 (27)
  Unknown                                                                        11 (5)                   7 (5)               4 (7)               ...
  Cell source                                                                                                                                     
  PBSC                                                                           163 (71)                 104 (73)            34 (63)             25 (76)
  BM/CB                                                                          67 (29)                  39 (27)             20 (37)             8 (24)
  Donor type                                                                                                                                      
  Allogeneic/unrelated                                                           171 (74)                 101 (71)            42 (78)             28 (85)
  Autologous                                                                     59 (26)                  42 (29)             12 (22)             5 (15)
  No. of transplantations                                                                                                                         
  1                                                                              187 (81)                 121 (85)            40 (74)             26 (79)
  2                                                                              40 (17)                  21 (15)             14 (26)             5 (15)
  3                                                                              3 (1)                    1 (1)               0 (0)               2 (6)
  Morphologic relapse                                                                                                                             
  No                                                                             219 (95)                 135 (94)            52 (96)             32 (97)
  Yes                                                                            11 (5)                   8 (6)               2 (4)               1 (3)
  Acute GVHD                                                                                                                                      
  Grade 0--2                                                                     133 (58)                 77 (54)             34 (63)             22 (67)
  Grade 3--4                                                                     32 (28)                  18 (13)             8 (15)              6 (18)
  FEV1 percentage prior to transplantation                                                                                                        
  \<80                                                                           49 (21)                  31 (22)             12 (22)             6 (18)
  ≥80                                                                            148 (64)                 93 (65)             32 (59)             23 (70)
  Missing                                                                        33 (14)                  19 (13)             10 (19)             4 (12)
  FEV1/FVC prior to transplantation                                                                                                               
  \<70                                                                           37 (16)                  23 (16)             10 (19)             4 (12)
  ≥70                                                                            162 (70)                 104 (73)            33 (61)             25 (76)
  Missing                                                                        31 (13)                  16 (11)             11 (20)             4 (12)
  D~LCO~ percentage prior to transplantation                                                                                                      
  \<80                                                                           109 (47)                 66 (46)             25 (46)             18 (55)
  ≥80                                                                            82 (36)                  53 (37)             18 (33)             11 (33)
  Missing                                                                        39 (17)                  24 (17)             11 (20)             4 (12)
  Days to first diagnosis of RSV infection after transplantation, median (IQR)   128.5 (50--422)          90.0 (50--407)      121.5 (48--405)     152.0 (114--499)
  Bronchiolitis obliterans prior to RSV infection                                                                                                 
  No                                                                             226 (98)                 143 (100)           52 (96)             31 (94)
  Yes                                                                            4 (2)                    0 (0)               2 (4)               2 (6)
  RSV testing method                                                                                                                              
  PCR                                                                            168 (73)                 97 (68)             44 (81)             27 (82)
  Non-PCR                                                                        62 (27)                  46 (32)             10 (19)             6 (18)
  Oxygen use at first diagnosis of RSV infection                                                                                                  
  None                                                                           201 (87)                 140 (98)            45 (83)             16 (48)
  ≤2 L/min                                                                       4 (2)                    ...                 3 (6)               1 (3)
  \>2 L/min                                                                      19 (8)                   3 (2)               6 (11)              10 (30)
  MV                                                                             6 (3)                    ...                 ...                 6 (18)
  Steroid use at first diagnosis of RSV infection                                                                                                 
  None                                                                           144 (63)                 95 (66)             30 (56)             19 (58)
  ≤1 mg/kg/day                                                                   68 (30)                  41 (29)             16 (30)             11 (33)
  \>1 mg/kg/day                                                                  18 (8)                   7 (5)               8 (15)              3 (9)

Data are no. (%) of subjects, unless otherwise indicated.

Abbreviations: BM, bone marrow; CB, cord blood; D~LCO~ diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume, 1 second; FVC, forced vital capacity; GVHD, graft-versus-host disease; IQR, interquartile range; PBSC, peripheral blood stem cell; PCR, polymerase chain reaction.

RESULTS {#s8}
=======

Patient Characteristics {#s9}
-----------------------

We identified 230 HCT recipients with RSV infection from 2003 through 2015. The median age at transplant receipt was 50 years (range, 0.5--71.6 years). The median time to initial diagnosis of RSV infection following transplantation was 128.5 days (interquartile range \[IQR\], 50--422 days). Of 197 patients who presented with URTI, 143 did not progress to LRTI (group 1), and 54 progressed to LRTI (group 2). Thirty-three subjects presented with LRTI (group 3). Comparisons of demographic variables for groups 1, 2, and 3 are shown in [Table 1](#T1){ref-type="table"}. Of 87 patients who developed or presented with LRTI, infection in 45 (52%) was defined as possible LRTI, and infection in 42 (48%) was defined as probable or proven LRTI. Only 5 probable cases were identified in the whole cohort. The percentage of subjects using \>2 L of supplemental oxygen per minute at diagnosis was compared among groups 1, 2, and 3 ([Table 2](#T2){ref-type="table"}) and was found to be highest in those presenting with LRTI (group 3; 48%). In group 3, 6 patients (18%) required mechanical ventilation at diagnosis.

###### 

Supplemental Oxygen Use and Mortality Outcomes Among Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection, by Site of RSV Detection

  Variable                           Groups 1 and 2, URTI, No. (%) (n = 197)   Group 2, LRTI, No. (%)   Group 3, LRTI, No. (%)   Groups 2 and 3, LRTI, No. (%)                                          
  ---------------------------------- ----------------------------------------- ------------------------ ------------------------ ------------------------------- --------- -------- --------- --------- ---------
  Oxygen use \>2 L/min                                                                                                                                                                                  
  At RSV infection diagnosis         9 (5)                                     17 (31)                  3 (11)                   14 (52)                         16 (48)   6 (33)   10 (67)   9 (20)    24 (57)
  By day 28                          31 (16)                                   21 (39)                  4 (15)                   17 (63)                         20 (61)   8 (44)   12 (80)   12 (27)   29 (69)
  Mechanical ventilation by day 28   8 (4)                                     8 (15)                   0 (0)                    8 (30)                          9 (27)    2 (11)   7 (47)    2 (4)     15 (36)
  Death by day 28                    4 (2)                                     6 (11)                   0 (0)                    6 (22)                          5 (15)    0 (0)    5 (33)    0 (0)     11 (26)

Abbreviations: LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection.

Supplemental Oxygen Use and Need for Mechanical Ventilation Following Diagnosis of RSV Infection {#s10}
------------------------------------------------------------------------------------------------

The proportion of patients who required any supplementation with \>2 L of oxygen per minute by day 28 after diagnosis of RSV infection was lowest for patients who presented with URTI (16% for groups 1 and 2) and highest among those who presented with LRTI (61% for group 3; [Table 2](#T2){ref-type="table"}). In cumulative incidence curves ([Figure 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}), patients presenting with LRTI were more likely to require supplemental oxygen or mechanical ventilation than patients presenting with URTI (*P* \< .0001 and *P* \< .0001, respectively, by the log-rank test). After LRTI diagnosis, the need for supplementation with \>2 L of oxygen per minute and mechanical ventilation by day 28 was higher in subjects who presented with LRTI than those who had progressed from URTI (61% and 27%, respectively, in group 3 vs 39% and 15%, respectively, in group 2). Further comparison between patients with possible LRTI versus those with proven/probable LRTI from groups 2 and 3 showed a higher need for supplemental oxygen use (69% vs 27%) and a higher need for mechanical ventilation (36% vs 4%) in patients with proven/probable LRTI versus those with possible LRTI. In cumulative incidence curves ([Figure 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}), supplemental oxygen use and mechanical ventilation from the time of LRTI were significantly higher for patients with proven/probable LRTI than for those with possible LRTI (*P* \< .0001 and *P* = .0003, respectively, by the log-rank test).

![*A* and *B*, Unadjusted cumulative incidence curves for time to first use of supplemental oxygen (*A*) and time to mechanical ventilation (*B*) at day 28 following initial diagnosis of respiratory syncytial virus (RSV) infection, categorized by group. *P* \< .0001, by the log-rank test (*A* and *B*). *C* and *D*, Unadjusted cumulative incidence curves for time to first use of supplemental oxygen (*C*) and time to mechanical ventilation (*D*) at day 28 following diagnosis of RSV lower respiratory tract infection (LRTI) in groups 2 and 3, categorized by possible versus proven/probable LRTI. *P* \< .0001, by the log-rank rest (*C*); *P* = .0003, by the log-rank test (*D*).](jix39001){#F1}

Risk factors for the time to first use of supplemental oxygen were evaluated in univariate modes among all patients from the time of initial diagnosis (Supplementary Table 1). Of the variables evaluated, only age at transplantation, LRTI (as a time-dependent variable), steroid use in the 2 weeks prior to diagnosis of RSV infection, and PCR use as the testing platform were associated with the outcome. In a multivariate model ([Table 3](#T3){ref-type="table"}), all variables except PCR as a testing method remained significant risk factors for supplemental oxygen use. Risk factors for mechanical ventilation were also evaluated in univariate and multivariate models, and only LRTI as a time-dependent risk factor remained significant (Supplementary Tables 2 and 3).

###### 

Multivariate Analysis of Risk Factors for Time to First Use of Supplemental Oxygen During the 28 Days After Diagnosis of Syncytial Virus (RSV) Infection

  Covariate                             HR (95% CI)         *P*
  ------------------------------------- ------------------- --------
  Recipient age at transplantation, y                       
  \<21                                  1                   
  21--60                                4.87 (1.47--16.2)   .01
  \>60                                  5.74 (1.64--20.1)   .006
  Steroid use at diagnosis                                  
  None                                  1                   
  ≤1 mg/kg/day                          1.92 (1.05--3.52)   .035
  \>1 mg/kg/day                         2.39 (1.02--5.61)   .045
  LRTI as time-dependent covariate                          
  No                                    1                   
  Yes                                   7.63 (4.33--13.4)   \<.001
  RSV testing method                                        
  Non-PCR                               1                   
  PCR                                   1.47 (.71--3.05)    .303

Data are for 230 hematopoietic cell transplant recipients.

Abbreviations: CI, confidence interval; HR, hazard ratio; LRTI, lower respiratory tract infection; PCR, polymerase chain reaction.

Supplemental Oxygen--Free Days Following RSV Infection Diagnosis {#s11}
----------------------------------------------------------------

Median numbers of supplemental oxygen--free days (and associated interquartile ranges) while alive, per definition 1, are shown in [Figure 3](#F3){ref-type="fig"}. The median number of supplemental oxygen--free days after URTI diagnosis for patients in groups 1 and 2 was 29 (IQR, 29--29 days). Group 3 patients with proven/probable LRTI were alive and free of supplemental oxygen use for a median of 16 days less than those in groups 1 and 2 from initial diagnosis (13 vs 29 days; *P* \< .0001). Further analysis of groups 2 and 3 from the start of LRTI indicated that the number of supplemental oxygen--free days was significantly influenced by how LRTI was defined. Group 2 and 3 patients with possible LRTI had significantly more supplemental oxygen--free days than patients with probable/proven LRTI (29 days \[IQR, 28--29 days\] vs 17 days \[IQR, 0--29 days\]; *P* \< .0001). Of the 9 subjects who died by day 28, only 3 had any supplemental oxygen--free days in that period. Thus, calculation of supplemental oxygen--free days per definition 2 did not change medians for any groups (Supplementary Table 4).

Mortality Following RSV Infection Diagnosis {#s12}
-------------------------------------------

Death only occurred for patients in groups 2 and 3 (11% and 15%, respectively, during the 28 days following LRTI; [Table 2](#T2){ref-type="table"}). A Kaplan-Meier curve for mortality for all subjects from the time of initial diagnosis (URTI for groups 1 and 2 and LRTI for group 3) is shown in [Figure 2A](#F2){ref-type="fig"}; curves differed significantly (*P* = .0002, by the log-rank test). Curves for mortality from the time of LRTI diagnosis (groups 2 and 3) are shown in [Figure 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}. No difference was noted in patients with LRTI, whether or not they had progressed from URTI or presented with LRTI (*P* = .54, by the log-rank test; [Figure 2B](#F2){ref-type="fig"}). The frequency of death was, however, influenced by the definition of LRTI. There were no deaths among patients defined as having possible LRTI; deaths were only observed in group 2 and 3 patients with probable or proven LRTI (26%; [Table 2](#T2){ref-type="table"} and [Figure 2C](#F2){ref-type="fig"}).

![Unadjusted Kaplan-Meier curves for overall survival at day 28 for groups 1 and 2 versus group 3 following initial diagnosis of respiratory syncytial virus (RSV) infection (*P* = .0002, by the log-rank test; *A*), for group 2 versus group 3 following RSV LRTI (*P* = .514, by the log-rank test; *B*), and for groups 2 and 3 possible versus groups 2 and 3 proven/probable (the log-rank test could not be performed because of a lack of events in possible group; *C*).](jix39002){#F2}

Sample Size Modeling {#s13}
--------------------

Given the mortality rates observed in this cohort and the potential for supplemental oxygen--free days to be considered as a relevant endpoint in clinical trials enrolling patients who develop RSV LRTI, we evaluated the differences in sample size requirements between mortality and supplemental oxygen--free day endpoints. [Table 4](#T4){ref-type="table"} provides sample size estimates comparing mortality and number of supplemental oxygen--free days by day 28 for subjects developing or presenting with proven/probable LRTI (proven/probable from groups 2 and 3). Based on a baseline 28-day mortality rate of 26% in subjects with proven/probable LRTI, a reduction by a conservative estimate of 10% (to a 28-day mortality rate of 16%) would require a sample size of 221 subjects per arm (with a type 1 error of 5% and a power of 80%). In contrast, a conservative increase in the number of supplemental oxygen--free days from 16 (the observed mean number of supplemental oxygen--free days in patients with proven/probable LRTI) to 22 would require 64 subjects per arm. Additional sample size calculations for more and less conservative changes in mortality and number of supplemental oxygen--free days are shown in [Table 4](#T4){ref-type="table"}, with similarly lower sample sizes required in the supplemental oxygen--free day endpoint.

###### 

Sample Size Estimates for Use of Supplemental Oxygen--Free Days as an End Point in Clinical Trials of Proven/Probable Respiratory Syncytial Virus Lower Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients

  End Point                                                                       
  ------------------------------------------------------------ ------------------ --------------------------
  Day 28 mortality rate, reduction from baseline,^b^ %         Odds Ratio         Recipients/Arm, No.^a^
  2.5                                                          0.874              4677
  5                                                            0.757              1128
  10                                                           0.542              260
  15                                                           0.352              105
  20                                                           0.182              52
  Oxygen-free days by day 28, increase from baseline,^c^ no.   Effect Size^^d^^   Recipients/Arm, No.^^e^^
  2                                                            0.164              586
  4                                                            0.328              147
  6                                                            0.492              66
  8                                                            0.656              38
  10                                                           0.82               25

Estimates were made on the assumptions of a type 1 error of 5% and a power of 80%.

^a^Calculated by a 2-sided Pearson χ^2^ test.

^b^The baseline value was 26%.

^c^The baseline value was 15 days.

^d^Calculated as the increase from baseline, divided by a SD of 12.2.

^e^Calculated by a 2-sided test.

DISCUSSION {#s14}
==========

In the present study, we established that clinical outcomes, including mortality and supplemental oxygen--free days, are significantly worse in HCT recipients with RSV detected in the lower respiratory tract (ie, those with probable/proven LRTI) than in patients with RSV detected in the upper respiratory tract only (ie, those with URTI and possible LRTI). Death due to any cause only occurred in patients with proven/probable LRTI. We also demonstrated significant reductions in the number of supplemental oxygen--free days for patients with proven/probable LRTI as compared to those with possible LRTI. These data support the use of supplemental oxygen--free days as a potential clinical endpoint that could be associated with significant reductions in sample size.

RSV infection in HCT recipients has historically been associated with significant mortality, with death rates of up to 55% in patients with LRTI \[[@CIT0009]\]. However, mortality rates have been declining, presumably because of changes in transplantation practices, such as declining use of myeloablative regimens and improved supportive care practices. Additionally, previous studies of RSV in HCT recipients have used different definitions of LRTI which may account for wide variations in endpoints, including progression to LRTI, supplemental oxygen use, and mortality \[[@CIT0001], [@CIT0010], [@CIT0011], [@CIT0015], [@CIT0018]\]. Current guidelines also include possible LRTI in recommendations for management of RSV \[[@CIT0019]\]. Furthermore, differences exist among transplant centers in the use of BAL for diagnosing LRTI due to respiratory viruses. In the present study, we sought to characterize clinical outcomes both by the clinical status at the time of presentation to care (ie, URTI \[group 1\], URTI with progression to LRTI \[group 2\], and LRTI \[group 3\]) and by the site of virologic detection (URTI only, possible LRTI, probable LRTI, or proven LRTI). We found substantial differences in supplemental oxygen use, the number of supplemental oxygen--free days, and mortality between subjects with and those without RSV detected in the lower respiratory tract. Our data demonstrate that subjects with possible LRTI required very little supplemental oxygen and had no deaths and that they are more similar to subjects with URTI only, regardless of initial presentation. Conversely, patients with proven/probable LRTI are the only subjects who died and had significantly higher use of supplemental oxygen. These data are consistent with a previous study evaluating parainfluenza virus LRTI in HCT recipients, in which outcomes in possible LRTI cases were significantly better than in proven/probable LRTI cases \[[@CIT0016]\]. Taken together, these data suggest that a less conservative approach to defining LRTI without determining whether RSV is truly in the lower respiratory tract (in cases where imaging findings are abnormal) may be clinically misleading and contributes to the finding that mortality rates appear to have decreased among patients with a diagnosis of RSV LRTI.

The number of supplemental oxygen--free days as an endpoint was also evaluated in the current study. Supplemental oxygen use correlates with acute lung injury, which, in turn, is associated with mortality in HCT recipients \[[@CIT0015], [@CIT0020], [@CIT0021]\]. Additionally, supplemental oxygen use typically requires hospitalization; thus, the number of supplemental oxygen--free days represent a composite endpoint that takes into account disease severity, need for hospitalization, and mortality. Our data showed significant decreases in supplemental oxygen--free days in subjects with any LRTI as compared to those with URTI, and further decreases were seen in subjects with proven/probable LRTI as compared to those with possible LRTI. Ventilator-free days were first defined in the 1990s and then introduced to the ARDSNet in 2002 by Schoenfeld et al \[[@CIT0022], [@CIT0023]\], and they have been used as an end point extensively in the intensive care unit literature. Several studies, including randomized controlled trials \[[@CIT0024]\] and limited studies of viral infections such as enteroviruses \[[@CIT0028]\], influenza virus \[[@CIT0029], [@CIT0030]\], and herpes viruses \[[@CIT0031]\] in critically ill patients, have since used this end point. Our definition of supplemental oxygen--free days is consistent with Schoenfeld's original definition for ventilator-free days in acute respiratory distress syndrome \[[@CIT0023]\], with 2 notable exceptions. First, given the low rates of mechanical ventilation in this cohort (7% overall), our study was not sufficiently powered to evaluate ventilator-free days and thus evaluated supplemental oxygen--free days. Generally, patients receiving \>2 L of supplementary oxygen per minute require hospital admission, and thus an increasing number of supplemental oxygen--free days still represents significant healthcare cost savings. Second, the effect of death was evaluated both with the traditional definition (wherein death at any point during the 28-day period gives a score of 0 supplemental oxygen--free days for that subject) and with a definition that allows any days prior to death during which no supplemental oxygen was used to be counted as supplemental oxygen--free days. This second definition was used, given the high levels of competing risk of death in transplant recipients. Ultimately, only 3 subjects had any supplemental oxygen--free days prior to death, and thus mean and median supplemental oxygen--free days did not vary greatly with use of either definition.

Numbers of supplemental oxygen--free days were significantly different among subjects, based on their initial presentation (groups 1, 2, and 3), as well as by the classification of LRTI (possible vs proven/probable; [Figure 3](#F3){ref-type="fig"}). The lowest median number of supplemental oxygen--free days occurred in patients presenting with proven/probable LRTI (13 days), followed by subjects with proven/probable LRTI regardless of presentation (17 days). In contrast, subjects with possible LRTI in either group 2 or 3 had a median of 29 supplemental oxygen--free days, the same as subjects with URTI only. These data, along with mortality outcomes outlined above, suggest that the prognosis of HCT recipients with RSV detected in the upper respiratory tract and radiographic abnormalities requires sampling of the lower respiratory tract (eg, BAL) to determine whether proven LRTI is present. Confirmation of RSV LRTI with BAL can provide useful prognostic information and may help stratify patients by risk and help prioritize expensive and intensive therapeutic options. Currently, ribavirin is the only antiviral available for specific treatment of RSV disease \[[@CIT0010], [@CIT0011], [@CIT0015], [@CIT0032]\]; however, cost remains a prohibitive barrier to its use, with an estimated cost of greater than \$250 000 for a 10-day course \[[@CIT0033]\]. Risk stratification based on confirmation of probable/proven LRTI may assist in treatment considerations for HCT recipients with RSV. In addition, several antivirals are in phase 2 trials for treatment of RSV infections in various populations \[[@CIT0005], [@CIT0034]\], including HCT recipients \[[@CIT0007], [@CIT0008]\], and risk stratification may help develop rational prevention and treatment strategies for immunocompromised patients with these agents.

![Supplemental oxygen--free days while alive following respiratory syncytial virus (RSV) infection. Bars represent interquartile ranges (IQRs).](jix39003){#F3}

Based on outcome data from the current study, we calculated estimated sample size requirements to compare the 28-day mortality rate and number of supplemental oxygen--free days by day 28 as endpoints in subjects with proven/probable LRTI ([Table 4](#T4){ref-type="table"}). Supplemental oxygen--free days have the potential to significantly reduce the per arm sample size, compared with a traditional mortality endpoint, and could potentially aid in designing clinical trials with feasible sample sizes while maintaining a clinically relevant endpoint. The most common criticisms of use of ventilator-free days as an endpoint is lack of consensus definitions and high levels of heterogeneity, thus making comparisons among studies difficult \[[@CIT0038]\]. Because this is the first-time that supplemental oxygen--free days has been evaluated for RSV infection in HCT recipients and because this is a single center study, further studies that implement strict criteria for evaluating the need for supplemental oxygen and apply consistent definitions are needed. In addition, accurate diagnosis of proven/probable LRTI may also play a significant role in enriching clinical trial recruitment for patients who are most likely to experience the adverse outcome, thus also reducing the sample size.

This study has several limitations. First, this is a retrospective review, and the use of BAL to evaluate LRTI is largely based on protocols at our center, which recommend BAL when RSV is detected in the upper respiratory tract and radiographic abnormalities are present. However, the decision to pursue bronchoscopy is ultimately left to the attending physician, and thus some potential probable or proven cases may have been missed. Despite this inherent limitation in capturing the proven/probable LRTI cases, we demonstrated differences in clinical outcomes between groups. Additionally, the definition of a supplemental oxygen--free day as one during which supplementation with ≤2 L of oxygen per minute was required relies on subjective clinical decisions that may not have a physiological correlate. However, the requirement of a sustained 48-hour period without use of \>2 L of supplemental oxygen per minute to be deemed an supplemental oxygen--free day should account for this inherent variability.

In conclusion, our data demonstrate that patients with RSV detected in the lower respiratory tract (ie, those with proven/probable LRTI) had worse outcomes than patients with RSV detected in the upper respiratory tract only despite the presence of radiographic abnormalities (ie, those with possible LRTI). The separation of LRTI into these groups could be useful in future outcomes research; however, validation of these results with other sites and protocols will be important. One potential application would be in cross-validating the immunodeficiency scoring index suggested for use in HCT recipients with RSV infection, to help develop consensus definitions \[[@CIT0014]\]. Furthermore, by using a more conservative approach to defining LRTI and implementing supplemental oxygen--free days as a surrogate clinical endpoint, we believe clinical trials may be able to use smaller sample sizes, thereby facilitating more-rapid development of novel agents to treat RSV infections in HCT recipients.
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